Dr. John Hansen, Who Made Marrow Transplants Safer, Dies at 76

His research expanded the pool of donors whose bone marrow was less likely to be rejected by patients with leukemia and other blood disorders.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Hansen, Dr. John Bone Marrow Deaths (Obituaries) Transplants Immune System Fred Hutchinson Cancer Research Center Source Type: news

Related Links:

Publication date: Available online 7 August 2019Source: The Lancet HaematologyAuthor(s): Farhad Ravandi, Rita Assi, Naval Daver, Christopher B Benton, Tapan Kadia, Philip A Thompson, Gautam Borthakur, Yesid Alvarado, Elias J Jabbour, Marina Konopleva, Koichi Takahashi, Steven Kornblau, Courtney D DiNardo, Zeev Estrov, Wilmer Flores, Sreyashi Basu, James Allison, Padmanee Sharma, Sherry Pierce, Allison PikeSummaryBackgroundOutcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better supportive care and recent introduction of novel targeted agents. Blocking PD-...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Contributors : Yoshikane Kikushige ; Yuichiro Semba ; Koichi AkashiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensThe branched-chain amino acid (BCAA) metabolism plays pleiotropic roles in homeostasis. Here we show that human acute leukemia-initiating cells (LICs), but not normal hematopoietic stem cells, are heavily addicted to the BCAA metabolism, irrespective of myeloid or lymphoid types. Human acute leukemia cells had a high level of BCAAs, transporting free BCAAs into the cytoplasm. Functional inhibition of BCAA transaminase-1 (BCAT1), a catalytic enzyme for BCAAs,...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
Contributors : Janus S Jakobsen ; Linea G Laursen ; Mikkel B Schuster ; Sachin Pundhir ; Nicolas Rapin ; Erwin Schoof ; Ying Ge ; Kristoffer Vitting-Seerup ; Coline Gentil ; Johan Jendholm ; Peter Hokland ; Jude Fitzgibbon ; Bo T PorseSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusCEBPA is a key hematopoietic transcription factor (TF), found mutated in 5-14% of all acute myeloid leukemia (AML) cases, but the direct molecular ramifications of this driver mutation remains elusive. To investigate CEBPA-mut...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Mus musculus Source Type: research
We focused on the construction of a prediction model for the bedside decision ‐making process and investigated the usefulness of machine learning (ML). Clinicians can refer to the model which was constructed by ML and select treatment options. ML may improve the decision‐making process for therapy in the diversified allo‐HSCT field. AbstractAlthough allogeneic hematopoietic stem cell transplantation (allo ‐HSCT) is a curative therapy for high‐risk acute leukemia (AL), some patients still relapse. Since patients simultaneously have many prognostic factors, difficulties are associated with the construction of a pat...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract Epithelial growth factor-like 7 (EGFL7) is a secretory protein with a well-characterized role in angiogenesis and the oncogenesis of certain solid tumors. Overexpression of EGFL7 is associated with adverse prognosis in patients with cytogenetically normal acute myeloid leukemia (CN-AML). However, whether this association persists after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear. To further clarify the prognostic role of EGFL7, seventy-one AML patients with EGFL7 expression data who underwent allo-HSCT from The Cancer Genome Atlas database were included and divided into ...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Authors: Martínez-Torres AC, Calvillo-Rodríguez KM, Uscanga-Palomeque AC, Gómez-Morales L, Mendoza-Reveles R, Caballero-Hernández D, Karoyan P, Rodríguez-Padilla C Abstract Acute lymphocytic leukemia (ALL) is the most common pediatric cancer. Currently, treatment options for patients with relapsed and refractory ALL mostly rely on immunotherapies. However, hematological cancers are commonly associated with a low immunogenicity and immune tolerance, which may contribute to leukemia relapse and the difficulties associated with the development of effective immunotherapies against thi...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Abstract Cancer Stem Cells (CSCs) are the subpopulation of cells present in the tumors with capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into an animal host. Therefore, the research work on the CSC has provided a promising approach for the improvement of cancer therapies in the future. The CSCs have a close connection with the cytokines related with the T helper 17 (Th17) cell and other factors present in the tumor microenvironment, and these play a pivotal role in tumor progression and metastasis. The properties of CSCs are well defined in various type of tumor which is main...
Source: Immunology Letters - Category: Allergy & Immunology Authors: Tags: Immunol Lett Source Type: research
Authors: Shi M, Jeanna Su R, Parmar KP, Chaudhry R, Sun K, Rao J, Chen M Abstract Leukemia is a group of progressive hematologic malignancies derived from hematopoietic stem cells (HSCs) in bone marrow which causes a large number of cancer deaths. Even with treatment such as traditional chemotherapy, targeted therapy, and allogeneic stem cell transplantation (allo-HSCT), the majority of patients in the end relapse with drug-resistance and the overall survival is dismal. Leukemic stem cells (LSCs) take responsibility for the evolution, relapse and drug-resistance of leukemia. Emerging studies demonstrate that CD123,...
Source: Cardiovascular and Hematological Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research
Hamadani M, Ganguly S, Bacher V, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba NS, Copelan E, Nathan S, Beitinjaneh AM, Savani B, Cerny J, Grunwald MR, Yared J, Wirk B, Nishihori T, Chhabra S, Olsson R, Bashey A, Gergis U, Popat U, Sobecks RM, Alyea EP, Saber W, Brown JR Abstract PURPOSE: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoiet...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract T-cell large granular lymphocyte (T-LGL) leukemia is a rare clonal proliferation of cytotoxic lymphocytes rarely described in solid organ transplant (SOT). We reviewed records from 656 kidney transplant recipients in follow-up at our Center from January 1998 to July 2017. In addition, we researched, through PubMed, further reports of T-LGL leukemia in SOT from March 1981 to December 2017. We identified six cases of T-LGL leukemia in our cohort of patients and 10 in the literature. This lymphoproliferative disorder was detected in one combined liver-kidney, one liver and 14-kidney transplant recipient...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
More News: Cancer | Cancer & Oncology | Health | Leukemia | Transplants